Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Barclays PLC boosted its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 118.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,819 shares of the company's stock after purchasing an additional 136,541 shares during the period. Barclays PLC owned 0.15% of Relay Therapeutics worth $1,783,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp grew its position in Relay Therapeutics by 15.7% in the second quarter. Bank of New York Mellon Corp now owns 354,667 shares of the company's stock worth $2,312,000 after acquiring an additional 48,219 shares in the last quarter. Rhumbline Advisers boosted its holdings in Relay Therapeutics by 4.8% in the second quarter. Rhumbline Advisers now owns 163,895 shares of the company's stock worth $1,069,000 after purchasing an additional 7,508 shares in the last quarter. Victory Capital Management Inc. increased its position in Relay Therapeutics by 11.2% during the second quarter. Victory Capital Management Inc. now owns 76,539 shares of the company's stock worth $499,000 after buying an additional 7,680 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in Relay Therapeutics by 661.7% during the second quarter. Los Angeles Capital Management LLC now owns 106,169 shares of the company's stock valued at $692,000 after buying an additional 92,230 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Relay Therapeutics by 19.4% in the second quarter. American Century Companies Inc. now owns 178,088 shares of the company's stock worth $1,161,000 after buying an additional 28,894 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company's stock.

Insider Activity at Relay Therapeutics

In related news, insider Peter Rahmer sold 32,156 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $4.15, for a total value of $133,447.40. Following the sale, the insider now owns 357,507 shares of the company's stock, valued at $1,483,654.05. The trade was a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Sanjiv Patel sold 100,000 shares of the firm's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $5.00, for a total transaction of $500,000.00. Following the transaction, the chief executive officer now owns 574,548 shares of the company's stock, valued at approximately $2,872,740. This represents a 14.82 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 162,319 shares of company stock worth $781,067. 4.32% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RLAY has been the topic of a number of analyst reports. Stifel Nicolaus reissued a "buy" rating and set a $28.00 price objective on shares of Relay Therapeutics in a report on Monday, September 16th. JMP Securities reissued a "market outperform" rating and issued a $21.00 price target on shares of Relay Therapeutics in a research report on Thursday, December 12th. HC Wainwright reduced their price objective on shares of Relay Therapeutics from $20.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th. Finally, Leerink Partners lowered their target price on shares of Relay Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 4th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Relay Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $20.50.

Relay Therapeutics Stock Performance

Shares of NASDAQ:RLAY traded down $0.38 on Friday, hitting $4.45. 11,847,678 shares of the company were exchanged, compared to its average volume of 3,316,278. The company's 50 day moving average price is $4.81 and its two-hundred day moving average price is $6.32. The firm has a market capitalization of $744.85 million, a price-to-earnings ratio of -1.70 and a beta of 1.60. Relay Therapeutics, Inc. has a one year low of $4.00 and a one year high of $12.07.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.14. During the same period in the prior year, the business earned ($0.54) EPS. Relay Therapeutics's revenue was down 100.0% compared to the same quarter last year. Research analysts predict that Relay Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.